HC Wainwright Issues Pessimistic Forecast for ETON Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Research analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for Eton Pharmaceuticals in a research report issued on Tuesday, November 26th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.05 per share for the quarter, down from their previous estimate of $0.09. HC Wainwright currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals' Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.11 EPS, FY2025 earnings at $0.37 EPS, FY2026 earnings at $0.81 EPS and FY2027 earnings at $1.25 EPS.

Separately, Craig Hallum increased their price target on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a "buy" rating in a report on Monday, October 28th.

Eton Pharmaceuticals Stock Performance

ETON stock traded up $0.29 during trading on Wednesday, hitting $12.74. 186,560 shares of the company's stock traded hands, compared to its average volume of 102,313. The business has a fifty day simple moving average of $8.23 and a 200 day simple moving average of $5.36. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $12.77. The stock has a market capitalization of $329.15 million, a price-to-earnings ratio of -56.05 and a beta of 1.25.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Westside Investment Management Inc. grew its stake in Eton Pharmaceuticals by 2.0% in the second quarter. Westside Investment Management Inc. now owns 585,400 shares of the company's stock worth $1,926,000 after purchasing an additional 11,440 shares in the last quarter. Thompson Siegel & Walmsley LLC bought a new position in shares of Eton Pharmaceuticals during the 2nd quarter worth $420,000. Renaissance Technologies LLC grew its position in shares of Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company's stock worth $350,000 after buying an additional 41,469 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in shares of Eton Pharmaceuticals during the second quarter valued at $3,095,000. Finally, Stonepine Capital Management LLC bought a new stake in shares of Eton Pharmaceuticals in the second quarter valued at about $362,000. Hedge funds and other institutional investors own 27.86% of the company's stock.

Insiders Place Their Bets

In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. bought 16,852 shares of Eton Pharmaceuticals stock in a transaction on Friday, October 4th. The shares were acquired at an average price of $6.77 per share, for a total transaction of $114,088.04. Following the completion of the purchase, the insider now directly owns 2,720,000 shares in the company, valued at approximately $18,414,400. This trade represents a 0.62 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders bought 85,600 shares of company stock valued at $462,674 over the last three months. 14.89% of the stock is owned by company insiders.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.